Session Details

F036 Evidence-Based Care for Hidradenitis Suppurativa: A Comprehensive Guidelines Update

Sat, Mar 20, 3:30 PM - 5:30 PM
2 CME Available Forum NEW

DESCRIPTION

The newly published American Academy of Dermatology and Hidradenitis Suppurativa Foundation (AAD-HSF) clinical practice guidelines establish a unified evidence-based standard for the medical and procedural management of hidradenitis suppurativa (HS). This forum will review the AAD-HSF guidelines and pair them with 2 complementary North American guidelines that extend the standard of care to comorbidity screening and to special patient populations including pregnancy, breastfeeding, pediatrics, malignancy, tuberculosis & viral hepatitis, and HIV.

LEARNING OBJECTIVES

1.

Apply the AAD-HSF clinical practice guideline recommendations for medical and procedural management of HS in routine clinical practice.

2.

Identify recommended comorbidity screening for patients with HS and outline the role of the dermatologist in initiating and coordinating that screening.

3.

Select evidence-based medical management strategies for patients with HS in special populations, including those who are pregnant, breastfeeding, pediatric, or affected by malignancy, tuberculosis, viral hepatitis, and/or HIV.

DIRECTOR

Haley Naik, MD, FAAD

Haley Naik, MD, FAAD

University of California, San Francisco

SPEAKERS

Ra'ed Alhusayen, MD, MSc, FAAD

Ra'ed Alhusayen, MD, MSc, FAAD

University of Toronto

Amit Garg, MD, FAAD

Amit Garg, MD, FAAD

Northwell Health

Lauren Orenstein, MD, FAAD

Lauren Orenstein, MD, FAAD

Emory University School of Medicine

DISCLOSURES

Ra'ed Alhusayen, MD, MSc, FAAD

AbbVie – Advisory Board(Honoraria), Speaker(Honoraria); Arcutis Biotherapeutics – Advisory Board(Honoraria); Biojamp – Speaker(Honoraria); Canadian Dermatology Association – Board of Directors(No Compensation Received); Canadian Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received); Celltrion – Advisory Board(Honoraria); Fresenius Kabi – Advisory Board(Honoraria); Incyte – Investigator(Fees), Speaker(Honoraria); janssen – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Kenvue – Advisory Board(Honoraria); Kyowa Kirin – Advisory Board(Honoraria); LEO Laboratories Ltd (LEO Pharma) – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Fees), Speaker/Faculty Education(Honoraria); Pfizer Inc. – Other(Equipment); Recordati rare diseases – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Fees); Sun Pharma Advanced Research Company (SPARC) – Advisory Board(Honoraria); UCB – Speaker/Faculty Education(Honoraria); UCB Pharma – Advisory Board(Honoraria);

Amit Garg, MD, FAAD

AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Bluefin Biomedicine – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Leo Pharma – Advisory Board(Honoraria); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Otsuka Pharmaceutical Co., Ltd. – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);

Haley Naik, MD, FAAD

23andMe – Consultant(Honoraria); AbbVie – Consultant(Honoraria), Other(Grants/Research Funding); Aristea Therapeutics, Inc. – Consultant(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); Dava Oncology – Consultant(Honoraria); Incyte – Other(Grants/Research Funding); Johnson and Johnson – Consultant(Honoraria); Medscape – Consultant (1099 relationship)(Fees); Nimbus Therapeutics – Consultant(Honoraria); Novartis – Consultant (1099 relationship)(Fees), Other(Grants/Research Funding); Radera Biotherapeutics, Inc. – Stockholder Private Company(Stock Options); Radera, Inc. – Stockholder Private Company(Stock Options); Sonoma Biotherapeutics – Consultant (1099 relationship)(Fees); UCB – Consultant (1099 relationship)(Fees), Other(Grants/Research Funding);

Lauren Orenstein, MD, FAAD

HS Foundation – Board of Directors(No Compensation Received); Incyte Corporation – Advisory Board(Fees), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Advisory Board(Fees); Novartis – Advisory Board(Fees), Investigator(Grants/Research Funding); Phrase Health – Stockholder(Stock); UCB Pharma – Advisory Board(Fees);